IPO Update: Kaleido Biosciences Seeks $100 Million IPO

Summary

  • Kaleido Biosciences has proposed terms for its U.S. IPO.
  • The firm is developing treatment candidates for urea cycle disorders.
  • It is still early stage, has no collaboration partners and no existing investor support for the IPO.
  • The IPO appears richly valued, so I'll be watching it from the sidelines.
  • This idea was discussed in more depth with members of my private investing community, IPO Edge. Start your free trial today »

Quick Take

Kaleido Biosciences (OTC:KLDO) intends to raise $100 million from the sale of its common stock, per an amended registration statement.

The company is developing microbiome-centric treatment candidates for hyperammonemia and other urea cycle disorders.

KLDO is seeking a high valuation for a very early stage firm with no existing investor support for the IPO.

Company & Technology

Lexington, MA-based Kaleido was founded in 2015 to develop therapeutic agents utilizing the body’s microbiome.

Management is headed by CEO Alison Lawton, who has been with the firm since December 2017 and was previously COO at Aura Biosciences.

Below is a brief overview video of the human microbiome:

READ FULL ARTICLE HERE